Literature DB >> 16153458

Abnormal expression of Rb pathway-related proteins in salivary gland acinic cell carcinoma.

Tingjiao Liu1, Enxin Zhu, Lihong Wang, Toshie Okada, Akira Yamaguchi, Norihiko Okada.   

Abstract

Salivary gland acinic cell carcinoma (ACC) is a relatively rare neoplasm, and limited information is available regarding its molecular pathogenesis. Because the deregulation of Rb pathway is common to most human tumors, we immunohistochemically investigated the expression of Rb pathway-related proteins, including Rb, Rb proteins phosphorylated at serine 780 and 795 (pRb-S780 and pRb-S795, respectively), cyclin D1, and p16INK4a in 18 cases of ACC. The expression of topoisomerase II-alpha and Ki-67 was also examined to evaluate cell proliferation. All the ACCs exhibited substantial numbers of positive cells against Rb antibody that recognizes both unphosphorylated and phosphorylated Rb proteins. The numbers of positive cells for pRb-S795 and cyclin D1 significantly increased in ACCs as compared with normal salivary glands. Double immunofluorescent staining demonstrated that pRb-S795 was colocalized with cyclin D1 in most tumor cells. However, neither significant change of the expression of Rb protein phosphorylated at serine 780 nor its colocalization with cyclin D1 was observed. The loss of p16INK4a is infrequent, but its expression was correlated with phosphorylated Rb proteins. Our results suggest that serine 795 but not serine 780 is the preferred phosphorylation site induced by cyclin D1. This phosphorylation appeared to be critical for inactivation of Rb-mediated growth suppression and may play an important role in the pathogenesis of ACC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16153458     DOI: 10.1016/j.humpath.2005.06.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Emodin elicits cytotoxicity in human lung adenocarcinoma A549 cells through inducing apoptosis.

Authors:  Wing-Yan Li; Yam-Fung Ng; Huan Zhang; Zi-Dong Guo; De-Jian Guo; Yiu-Wa Kwan; George Pak-Heng Leung; Simon Ming-Yuen Lee; Peter Hoi-Fu Yu; Shun-Wan Chan
Journal:  Inflammopharmacology       Date:  2013-08-22       Impact factor: 4.473

2.  Dysregulation of the Rb pathway in recurrent pleomorphic adenoma of the salivary glands.

Authors:  Ana Amélia de Souza; Albina Altemani; Fabricio Passador-Santos; Cecilia Pedroso Turssi; Ney Soares de Araujo; Vera Cavalcanti de Araújo; Andresa Borges Soares
Journal:  Virchows Arch       Date:  2015-07-09       Impact factor: 4.064

3.  Differential expression of p16(INK4A) and cyclin D1 in benign and malignant salivary gland tumors: a study of 44 Cases.

Authors:  G Jour; K West; V Ghali; D Shank; G Ephrem; B M Wenig
Journal:  Head Neck Pathol       Date:  2013-01-13

4.  Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands.

Authors:  Florian Haller; Matthias Bieg; Rainer Will; Cindy Körner; Dieter Weichenhan; Alexander Bott; Naveed Ishaque; Pavlo Lutsik; Evgeny A Moskalev; Sarina K Mueller; Marion Bähr; Angelika Woerner; Birgit Kaiser; Claudia Scherl; Marlen Haderlein; Kortine Kleinheinz; Rainer Fietkau; Heinrich Iro; Roland Eils; Arndt Hartmann; Christoph Plass; Stefan Wiemann; Abbas Agaimy
Journal:  Nat Commun       Date:  2019-01-21       Impact factor: 14.919

5.  Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion.

Authors:  C Christofer Juhlin; Sylvia L Asa; Kenbugul Jatta; Homeyra Naserhojati Rodsari; Ivan Shabo; Felix Haglund; Brett Delahunt; Hemamali Samaratunga; Lars Egevad; Anders Höög; Jan Zedenius
Journal:  Head Neck Pathol       Date:  2020-06-09

6.  B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation.

Authors:  Cinzia Giagulli; Francesca Caccuri; Simone Zorzan; Antonella Bugatti; Alberto Zani; Federica Filippini; Ekta Manocha; Pasqualina D'Ursi; Alessandro Orro; Riccardo Dolcetti; Arnaldo Caruso
Journal:  Cancer Gene Ther       Date:  2020-10-22       Impact factor: 5.987

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.